On Friday 28 March at 14:00, Judit Prat-Duran defends her PhD dissertation entitled "Transglutaminase 2 as a therapeutic target in chronic kidney disease".

Chronic kidney disease (CKD) affects millions worldwide, often leading to kidney failure. A key player in this process is an enzyme called Transglutaminase 2 (TG2), which contributes to irreversible kidney scarring (fibrosis) when in its active state. In our research, we explored whether blocking TG2’s activity using a specific inhibitor (LDN27219) could slow down kidney damage. Using both mouse models and human kidney tissue samples, we found that the inhibitor reduced the production of fibrosis-related proteins. However, it did not completely stop scar tissue from forming. These findings suggest that targeting TG2 could be a promising strategy for treating CKD, but more research is needed to fully understand its effects. By better understanding how kidney scarring develops, we hope to contribute to new therapies that can protect kidney function and improve patients' lives.

The summary is written by the PhD student.

The defence is public and takes place in Auditorium A, Aarhus University, Ole Worms Allé. Please see the press release for more information. 

Contact

PhD student Judit Prat-Duran
Mail: jprat@biomed.au.dk 
Phone: (+45) 81920373

Read full press release